Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)
(2019)
Journal Article
Robertson, J. F., Coleman, R. E., Cheung, K.-L., Evans, A., Holcombe, C., Skene, A., …Gee, J. M. (2020). Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26(7), 1574-1585. https://doi.org/10.1158/1078-0432.CCR-19-3053
© 2020 American Association for Cancer Research Inc.. All rights reserved. Purpose: The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therape... Read More about Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT).